Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
Quick Facts
What This Study Found
Among 125,474 US adults, 65% without diabetes discontinued GLP-1 RAs within one year vs. 47% with diabetes. Weight loss predicted staying on treatment; GI side effects and lower income predicted stopping.
Key Numbers
125,474 adults (65.4% women, mean age 54.4). 1-year discontinuation: 64.8% without T2D, 46.5% with T2D. Each 1% weight loss reduced discontinuation hazard by 3.1-3.3%. GI adverse events: HR 1.19-1.38 for discontinuation. Income >$80K: HR 0.72 for discontinuation (T2D only). 1-year reinitiation: 36.3% without T2D, 47.3% with T2D.
How They Did This
Retrospective cohort using electronic health records from multiple US health systems. 2018-2023. Kaplan-Meier for discontinuation/reinitiation. Time-varying Cox regression for predictors. Up to 4-year follow-up.
Why This Research Matters
This is the largest study of GLP-1 RA adherence patterns. It reveals that most patients stop these drugs within a year, especially those using them for weight loss without diabetes, highlighting a major treatment gap.
What This Study Doesn't Tell Us
EHR-based, may miss prescriptions filled outside system. Cannot distinguish intentional discontinuation from access barriers. Observational design. US-specific. Newer agents (tirzepatide) had shorter follow-up.
Trust & Context
- Original Title:
- Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
- Published In:
- JAMA network open, 8(1), e2457349 (2025)
- Authors:
- Rodriguez, Patricia J, Zhang, Vincent, Gratzl, Samuel, Do, Duy, Goodwin Cartwright, Brianna, Baker, Charlotte, Gluckman, Ty J, Stucky, Nicholas, Emanuel, Ezekiel J
- Database ID:
- RPEP-13288
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13288APA
Rodriguez, Patricia J; Zhang, Vincent; Gratzl, Samuel; Do, Duy; Goodwin Cartwright, Brianna; Baker, Charlotte; Gluckman, Ty J; Stucky, Nicholas; Emanuel, Ezekiel J. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.. JAMA network open, 8(1), e2457349. https://doi.org/10.1001/jamanetworkopen.2024.57349
MLA
Rodriguez, Patricia J, et al. "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.." JAMA network open, 2025. https://doi.org/10.1001/jamanetworkopen.2024.57349
RethinkPeptides
RethinkPeptides Research Database. "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Recep..." RPEP-13288. Retrieved from https://rethinkpeptides.com/research/rodriguez-2025-discontinuation-and-reinitiation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.